[Healthy persons versus patients with diabetes mellitus type 2--choosen parameters in serum and subcutaneous abdominal adipose tissue].

Unlabelled: Endocrinal products of adipocytes (PPARgamma, A-FABP, E-FABP, leptin, adiponectin and others) modulate insulin tissue sensitivity enabling them to participate in the ethiopathogenesis of diabetes mellitus type 2 (DM2T). Persons with DM2T are characterised by typical changes in lipid spectrum (lower HDL-cholesterol and higherTAG) and in the endocrinal function of subcutaneous adipose tissue; adipocytes produce more PPARgamma, A-FABP and E-FABP and less adiponectin.
Aims of the Study: To measure chosen markers of metabolic syndrome (MS) in serum and in abdominal subcutaneous adipose tissue in healthy persons and patients with DMT2, to determine basic statistical characteristics of investigated parameters and to discus their role in the genesis and progress of the MS.
Methods: Samples of blood and abdominal subcutaneous adipose tissue were collected from each participant (healthy: 7 men and 8 women; diabetics: 18 men, 11 women) to investigate the levels of HDL, TAG, insulin, C-peptide, glycaemia and the concentrations of A-FABP, E-FABP, leptin, adiponectin, resistin, PPARgamma and TNFalpha.
Results: In most cases the average concentration of investigated parameters in serum was higher in persons with DM 2 regardless of gender. Lower values were only found for HDL and adiponectin. The same situation prevailed in the subcutaneous adipose tissue. Values of most other parameters (A-FABP, E-FABP, and PPARgamma) were also higher in patients. The values of measured parameters not only differed in healthy and in sick persons but depended on gender. The increase/decrease in concrete parameters was greater in diabetic women than diabetic men.
Conclusion: Higher concentrations of A-FABP, E-FABP in serum and in subcutaneous adipose tissue in diabetic persons also higher concentrations of PPARgamma in subcutaneous adipose tissue suggest that these investigated parameters are closely associated with obesity and MS. We can assume that in the near future these parameters will be used in clinical work for diagnosis of this syndrome.